34 Belzutifan Plus Lenvatinib Versus Cabozantinib in Post–PD-(L)1 Renal Cell Carcinoma: Health-Related Quality-of-Life Outcomes in the Phase 3 LITESPARK-011 Study - Manuela Schmidinger; Daniel Y C Heng; Ray McDermott; Se Hoon Park; Mauricio Burotto; Roberto Iacovelli; Elena Verzoni; Masatoshi Eto; Hernan J Cutuli; Bogdan Zurawski; Camillo Porta; Sylvie Rottey; et al. (The Oncologist, 2026)